Electroencephalography Systems Market Size will gain traction between 2022 and 2028 driven by advancements in brain monitoring devices. Rising cases of neurological disorders in advanced and emerging economies have encouraged leading companies to boost the manufacturing of electroencephalography systems devices.
The anticipated trends in high blood sugar, high body mass index and smoking suggest the number of people with dementia could rise exponentially. Researchers at the University of Washington School of Medicine projects over 152 million people to suffer from dementia by 2050.
An electroencephalography system help detects abnormalities in the electrical activity of the brain or brain waves. The EEG has become instrumental in assessing several kinds of disorders and could be used to diagnose disorders, including Alzheimer's disease, sleep disorder and certain psychoses. Approximately 5.8 million people in the U.S. aged 65 and older live with Alzheimer's disease. Soaring demand for minimally invasive and non-invasive devices will augur well for the industry outlook.
In terms of modalities, portable EEG systems market share will grow with an increasing focus on technological advancements, including raw data acquisition and lightweight. Researchers have increased investments in cognitive psychology, neuroscience and psychological activities. With a rise in sleep disorders and cases of neurodegenerative, end-users will continue to invest in portable devices.
Based on application, ambulatory EEG will account for a considerable share of the global market during the forecast period. The growth could be attributed to drivers, such as longer monitoring outside a hospital setting or an office. Considering that it records brain activity over several days to boost the chance of catching seizure activity, industry participants are expected to seek ambulatory EEGs.
North America electroencephalography systems market share will expand with increasing cases of neurodegenerative disorders. The U.S. and Canada have also witnessed growth in healthcare infrastructure and robust supply chain. Strong reimbursement policies have made the region a highly sought destination for the treatment of brain nervous disorders.
A host of companies is profiled in the global market with leading players emphasizing organic and inorganic strategies, including mergers & acquisitions, product offerings, collaborations and R&D activities. Cadwell Laboratories Inc., Medtronic, Neurowave Systems Inc., BrainScope Company Inc, Noraxon U.S.A., Inc., Covidien Medical Devices, Compumedics Limited, Rimed Ltd. and Neurowave Systems Inc., among others, are poised to foster the business outlook.
In January 2021, Medtronic announced the launch of its first enrollment in ADAPT-PD trail for adaptive deep brain stimulation (aDBS). The trial will assess the efficacy and safety of aDBS in patients with Parkinson’s Disease. The study is likely to take place across 12 cities in Europe, the U.S. and Canada.
The COVID-19 outbreak disrupted the healthcare industry with the demand for remote monitoring and patient engagement solutions soaring exponentially. Several healthcare facilities are likely to fuel their patient monitoring towards home care settings. The pandemic furthered the demand for ventilators, such as respiratory devices to set up COVID-19 ICUs. Researchers are projected to assess the effects of rescue therapies with ventilation on the brain to help select therapies for coronavirus patients. Video telemetry could gain uptick across North America and Europe, auguring well for market share over the coming years.
Bullish government initiatives on the development of innovative and sophisticated devices will work well for the industry size expansion. Growing cases of neurological disorders will further push the industry growth.
Market, By Product
Market, By Modalities Million)
Market, By Application
Market, By End-use
The above information is provided for the following regions and countries: